Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:00 pm Sale |
2024-12-31 | 13G | ALX Oncology Holdings Inc. ALXO |
TANG CAPITAL PARTNERS LP | 3,296,883 6.300% |
-743,917 (-18.41%) |
Filing History |
| 2025-02-14 4:00 pm Sale |
2024-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
TANG CAPITAL PARTNERS LP | 1,641,945 3.000% |
-2,860,912 (-63.54%) |
Filing History |
| 2025-02-14 4:00 pm Sale |
2024-12-31 | 13G | Outlook Therapeutics, Inc. OTLK |
TANG CAPITAL PARTNERS LP | 1,682,502 6.400% |
-533,349 (-24.07%) |
Filing History |
| 2024-09-26 4:00 pm Sale |
2023-12-26 | 13G | Reneo Pharmaceuticals, Inc. RPHM |
TANG CAPITAL PARTNERS LP | 294,626 8.800% |
-38,374 (-11.52%) |
Filing History |
| 2024-08-22 4:00 pm Purchase |
2024-08-12 | 13G | ALX Oncology Holdings Inc. ALXO |
TANG CAPITAL PARTNERS LP | 4,040,800 7.700% |
4,040,800 (New Position) |
Filing History |
| 2024-07-22 9:02 pm Purchase |
2024-07-12 | 13G | HilleVax, Inc. HLVX |
TANG CAPITAL PARTNERS LP | 4,712,954 9.500% |
4,712,954 (New Position) |
Filing History |
| 2024-07-22 4:50 pm Purchase |
2024-07-10 | 13G | Agile Therapeutics, Inc. AGRX |
TANG CAPITAL PARTNERS LP | 426,153 6.200% |
426,153 (New Position) |
Filing History |
| 2024-04-19 06:04 am Purchase |
2024-04-16 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
TANG CAPITAL PARTNERS LP | 4,502,857 8.200% |
4,502,857 (New Position) |
Filing History |
| 2024-03-28 4:00 pm Purchase |
2024-03-18 | 13G | Outlook Therapeutics, Inc. OTLK |
TANG CAPITAL PARTNERS LP | 2,215,851 9.990% |
2,215,851 (New Position) |
Filing History |
| 2024-02-16 4:00 pm Sale |
2024-02-14 | 13D | Theseus Pharmaceuticals, Inc. THRX |
TANG CAPITAL PARTNERS LP | 100 100.000% |
-3,254,926 (-100.00%) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
TANG CAPITAL PARTNERS LP | 87,594 3.000% |
-25,062 (-22.25%) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | AnaptysBio, Inc. ANAB |
TANG CAPITAL PARTNERS LP | 1,950,609 7.300% |
-678,069 (-25.80%) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | AVROBIO, Inc. AVRO |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-225,417 (Position Closed) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | bluebird bio, Inc. BLUE |
TANG CAPITAL PARTNERS LP | 85,000 0.900% |
-146,776 (-63.33%) |
Filing History |
| 2024-02-14 4:00 pm Purchase |
2023-12-31 | 13G | Evolus, Inc. EOLS |
TANG CAPITAL PARTNERS LP | 3,097,399 5.400% |
58,667 (+1.93%) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | Quince Therapeutics, Inc. QNCX |
TANG CAPITAL PARTNERS LP | 3,220,000 7.500% |
-400,000 (-11.05%) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-269 (Position Closed) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
TANG CAPITAL PARTNERS LP | 1,753,335 2.500% |
-2,584,820 (-59.58%) |
Filing History |
| 2024-02-14 4:00 pm Purchase |
2023-12-31 | 13G | Adicet Bio, Inc. ACET |
TANG CAPITAL PARTNERS LP | 5,900,000 7.800% |
3,628,480 (+159.74%) |
Filing History |
| 2024-02-14 4:00 pm Purchase |
2023-12-31 | 13G | Altimmune, Inc. ALT |
TANG CAPITAL PARTNERS LP | 2,750,000 5.100% |
49,550 (+1.83%) |
Filing History |